News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Baxter International, Inc. (BAX) Receives Approval For PREFLUCEL Seasonal Influenza Vaccine in Austria



9/30/2010 8:54:47 AM

VIENNA, Austria--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults and the elderly. PREFLUCEL is manufactured using Baxter’s proprietary advanced Vero cell technology.

Read at BioSpace.com


comments powered by Disqus
   
Influenza
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES